InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,700.00
(
-0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
0.00%
)
Bitcoin
62,682.94
(
-0.80%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1063
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 336

Sunday, 09/02/2018 10:23:57 AM

Sunday, September 02, 2018 10:23:57 AM

Post# of 438
ZIOP has been developing a novel CAR-T platform and an IL-2 platform (gene therapy for solid tumors )

6/18 FDA placed a clinical hold on Ph1 CAR-T trial for relapsed/refractory leukemia/lymphoma.

At ASCO, ZIOP presented survival data from a Ph1 combo (IL-2 + Veledimex) study. Overall survival was 12.7 months for this injection therapy.

There is much skepticism regarding intratumoral injection therapies.

Cash runway does not extend thru H1/19.

I won't touch this during tax loss season.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up